For this review we screened the literature for possible candidates of drug repurposing in ANOCA treatment and identified two promising targets: Soluble Guanylate Cyclase (sGC) Stimulators and Endothelin-1-receptor (ET-1) blockers, both originally approved for the treatment of pulmonary hypertension (PH). The gene discussed is SGCB; the disease is pulmonary hypertension.